Sanofi (SNY): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Sanofi ( SNY) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 1.6%. By the end of trading, Sanofi rose $0.59 (1.1%) to $51.82 on heavy volume. Throughout the day, 3,259,439 shares of Sanofi exchanged hands as compared to its average daily volume of 1,804,400 shares. The stock ranged in a price between $51.28-$51.93 after having opened the day at $51.89 as compared to the previous trading day's close of $51.23. Other companies within the Health Care sector that increased today were: Agios Pharmaceuticals ( AGIO), up 27.8%, Questcor Pharmaceuticals ( QCOR), up 18.7%, Idenix Pharmaceuticals ( IDIX), up 12.4% and Flamel Technologies ( FLML), up 8.7%.

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Sanofi has a market cap of $137.8 billion and is part of the drugs industry. Shares are down 4.5% year to date as of the close of trading on Friday. Currently there are 2 analysts that rate Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity.

On the negative front, Puma Biotechnology ( PBYI), down 18.3%, Aquinox Pharmaceuticals ( AQXP), down 15.3%, Ohr Pharmaceutical ( OHRP), down 13.7% and RXi Pharmaceuticals ( RXII), down 12.8% , were all laggards within the health care sector with Teva Pharmaceutical Industries ( TEVA) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Sanofi Has Good Potential Upside

European Pharma Companies Slip on MS Pricing Probe